{6-[3-(2-Chloro-phenyl)-1-methyl-ureido]-pyrimidin-4-yl}-(4-morpholin-4-yl-phenyl)-carbamic acid tert-butyl ester | 903587-22-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: {6-[3-(2-Chloro-phenyl)-1-methyl-ureido]-pyrimidin-4-yl}-(4-morpholin-4-yl-phenyl)-carbamic acid tert-butyl ester
• CAS: 903587-22-4
• 化学式: C₂₇H₃₁ClN₆O₄
• 分子量: 539.034
• InChiKey: GYNVKKJHXJCSQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.71
• 重原子数：
  38.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  100.13
• 氢给体数：
  1.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  {6-[3-(2-Chloro-phenyl)-1-methyl-ureido]-pyrimidin-4-yl}-(4-morpholin-4-yl-phenyl)-carbamic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 3-(2-Chlorophenyl)-1-methyl-1-(6-(4-morpholinophenylamino)pyrimidin-4-yl)urea
  参考文献：
  名称：

  Development of N-4,6-pyrimidine-N-alkyl-N′-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase

  摘要：

  A new class of lymphocyte specific tyrosine kinase (lck) inhibitors based on an N-4,6-pyrimidine-N-alkyl-N'-phenyl urea scaffold is described. Many of these compounds showed low-nanomolar inhibition of lck kinase activity as well as IL-2 synthesis from Jurkat cells. One of these analogs, 7i, was shown to be orally efficacious by in vivo testing in a rat adjuvant-induced arthritis study. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.072
• 作为产物：
  描述：

  4-(4-吗啉基)苯胺 在 sodium hydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲苯 为溶剂， 反应 0.25h， 生成 {6-[3-(2-Chloro-phenyl)-1-methyl-ureido]-pyrimidin-4-yl}-(4-morpholin-4-yl-phenyl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Development of N-4,6-pyrimidine-N-alkyl-N′-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase

  摘要：

  A new class of lymphocyte specific tyrosine kinase (lck) inhibitors based on an N-4,6-pyrimidine-N-alkyl-N'-phenyl urea scaffold is described. Many of these compounds showed low-nanomolar inhibition of lck kinase activity as well as IL-2 synthesis from Jurkat cells. One of these analogs, 7i, was shown to be orally efficacious by in vivo testing in a rat adjuvant-induced arthritis study. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.072